News | October 06, 2009

Three-Year TAXUS ATLAS Data Shows Safety, Efficacy Over TAXUS Liberté

October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberté Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS Express Stent.

The TAXUS ATLAS Small Vessel Trial was designed to evaluate the long-term safety and efficacy of the 2.25 mm diameter TAXUS Liberté Atom Stent in small coronary vessels. The TAXUS ATLAS Long Lesion Trial was designed to assess the long-term safety and efficacy of the TAXUS Liberté Long 38 mm stent in patients with long coronary lesions. Boston Scientific remains the only company to offer both 2.25 mm diameter and 38 mm length drug-eluting coronary stents in the United States.

Three-year results from the TAXUS ATLAS Small Vessel Trial demonstrated a statistically significant reduction in the rate of target lesion revascularization (TLR) in small vessels treated with the TAXUS Liberté Atom as compared to the TAXUS Express Atom Stent (10 vs. 22.1 percent), representing a 55 percent relative risk reduction. Additionally, the three-year MACE rate for the TAXUS Liberté Atom was 19.5 percent as compared to 32.4 percent for the TAXUS Express Atom, a relative reduction of 40 percent. The composite safety measure of cardiac death or myocardial infarction (MI) remained numerically lower at three years for the TAXUS Liberté Atom as compared to the TAXUS Express Atom (6.5 vs. 7.4 percent).

“The TAXUS ATLAS Small Vessel Trial showed a sustained and significantly reduced risk of revascularization in small vessels for the TAXUS Liberté Atom Stent as compared to the TAXUS Express Atom Stent out to three years,” said Mark A. Turco, M.D., director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and coprincipal investigator of the trial. “Positive three-year data from the TAXUS ATLAS Long Lesion Trial showed the TAXUS Liberté Long Stent significantly reduces the risk of MI and cardiac death in long lesions compared to the TAXUS Express Stent, while reporting zero percent stent thrombosis. These data, combined with the previously reported reduction in nine-month late-loss, suggest that these improvements are likely the result of the thinner struts and improved stent geometry of the TAXUS Liberté Stent.”

In the TAXUS ATLAS Long Lesion Trial, the TAXUS Liberte Long demonstrated significantly improved safety outcomes when treating long lesions compared to the TAXUS Express. The rate of cardiac death showed a significant 78 percent reduction in patients treated with the TAXUS Liberté Long compared to the TAXUS Express (1.5 vs. 6.7 percent). Overall MI showed a significant 72 percent reduction at three years in patients receiving a single TAXUS Liberté Long compared to a single TAXUS Express (2.9 vs. 10.4 percent). This improvement was primarily driven by a significant reduction in non-Q wave MI. The TAXUS Liberté Long had zero stent thrombosis at three years using either the Protocol definition or the ARC definite/probable definition, while the control TAXUS Express reported 0.8 percent stent thrombosis using the Protocol definition and 3.9 percent using the ARC definition.

For more information: www.bostonscientific.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init